share_log

健康元(600380.SH)：吸入用复方异丙托溴铵溶液获得菲律宾药品注册批件

Health Source (600380.SH): Compound ipratropium bromide solution for inhalation obtained drug registration approval in the Philippines

Gelonghui Finance ·  Jan 9 05:13

On January 9, Gelonghui Health Yuan (600380.SH) announced that the company received a drug registration certificate for compound ipratropium bromide solution for inhalation approved and issued by the Philippine Food and Drug Administration. The company's self-developed compound ipratropium bromide solution for inhalation (hereinafter referred to as this product) obtained the drug registration approval issued by the State Drug Administration in April 2019. This product is a combination of ipratropium bromide and salbutamol sulfate. It can act in combination with muscarine and beta-2-adrenaline receptors in the lungs to quickly relieve bronchospasm by relaxing smooth airway muscle and improving symptoms. Clinical practice has proven that the curative effect of this product is superior to monotherapy. It is particularly suitable for patients requiring the combined use of various bronchodilators. It is a commonly used clinical drug for patients with asthma and chronic obstructive pulmonary disease.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment